Skip to main content
Premium Trial:

Request an Annual Quote

PathoQuest, Charles River Laboratories Broaden Biologics Partnership

NEW YORK (GenomeWeb) – PathoQuest and Charles River Laboratories announced today that they have further expanded their previously announced partnership to provide next-generation sequencing services to the biologics industry.

As part of the collaboration, Charles River will directly invest an unspecified amount in PathoQuest.

"Our partnership with PathoQuest is integral to our ability to provide the most sensitive testing methods to our clients in order to ensure the safety of biological products produced by the biopharmaceutical industry," Greg Beattie, Charles River's corporate VP, global biologics testing solutions said in a statement.

"We anticipate Charles River's global footprint and biologics-industry leadership will enable the further growth and expansion of our platform," PathoQuest President and CEO Jean-François Brepson said in a statement.